ERBB2 and neoplasm: It has also been observed that the immune system substantially contributes to the therapeutic effects of Her-2-targeted antibodies and the treatment with trastuzumab may increase tumor expression of PD-L1, which is potentially driving resistance to trastuzumab (14).